Who should not take Lusutrombopag?

Lusutrombopag is an oral thrombopoietin receptor agonist, mainly used in patients with chronic liver disease to increase platelet counts and reduce the risk of bleeding before planned invasive procedures. However, not all patients are suitable for using this drug, and certain groups of people need to be extra cautious when taking it or avoid using it to ensure the safety of the drug.

First of all, Rutrombopag should not be used in patients with severe hepatic insufficiency or liver failure. Although this drug is used in patients with chronic liver disease, when liver function is extremely impaired, drug metabolism may be abnormal, resulting in high blood concentrations or unpredictable drug effects, thereby increasing the risk of blood clots or bleeding. Therefore, for patients with Child-Pugh C grade or with obvious liver function abnormalities, medication should be carefully decided after evaluation by a doctor.

Second, Rutrombopag should be avoided in patients with existing thrombotic disorders or a high risk of thrombosis. Medications may increase the risk of blood clots by promoting platelet production and increasing platelet counts. Patients with previous deep vein thrombosis, pulmonary embolism, cerebral thrombosis or progressive arterial thrombotic events need to be used under strict monitoring or even be considered disabled. Doctors will assess the patient's past medical history and risk of blood clots before taking medication, and develop an individualized treatment plan.

In addition, patients who are allergic to Rutrombopag or its ingredients should not use it. During medication, if allergic reactions occur, including rash, itching, difficulty breathing, or a drop in blood pressure, the medication should be discontinued immediately and emergency treatment should be sought. The safety of use by children, pregnant women or lactating women has not been fully studied, and the decision whether to use it must be made after assessing the risks under the guidance of a professional doctor. Overall, following strict medication indications and monitoring specifications is the key to ensuring the safe and effective role of Rutrombopag.

Reference materials:https://www.drugs.com/pro/mulpleta.html